Rescue treatment with rituximab-CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] therapy and alemtuzumab (R-CHOP-A) in refractory or recidivant patients with chronic lymphocytic leukemia after purine-analogous treatment.

Trial Profile

Rescue treatment with rituximab-CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] therapy and alemtuzumab (R-CHOP-A) in refractory or recidivant patients with chronic lymphocytic leukemia after purine-analogous treatment.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Alemtuzumab; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2012 Company added as trial sponsor as reported by ClinicalTrials.gov.
    • 29 Dec 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 29 Dec 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top